glp 1 compounded semaglutide Oral Semaglutide for Weight Loss

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

24.54

★★★★☆4.8 (126)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

23.35

★★★★★4.9 (98)

🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending

24.77

★★★★★5.0 (157)

Retatrutide just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a phase 2 study: • Up to 24.2% mean weight loss at 48 weeks •

23.46

★★★★★4.7 (84)

These numbers are shocking. It's like we got a new frontier AI model but for the body. Lilly's phase 3 results for retatrutide: > highest dose lost 28.3% of body weight in

25.68

★★★★★4.9 (203)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

25.20

★★★★★5.0 (176)

Retatrutide: breakthrough… or still too early? Retatrutide is an investigational triple-hormone receptor agonist (GLP-1 + GIP + glucagon) designed to go beyond current metabolic therapies by targeting appetite, energy expenditure, and liver

24.41

★★★★★4.8 (132)